YearPaper
2008 Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia. 2008 Oct;22(10):1841–8. Review.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18754034
2008 Li S, Kralovics R, De Libero G, Theocharides A, Gisslinger H, Skoda RC. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood 2008, 111: 3863–3866. (abstract)
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18195094
2008 Liu K, Kralovics R, Rudzki Z, Grabowska B, Buser AS, Olcaydu D, Gisslinger H, Tiedt R, Frank P, Okon K, Van der Maas APC and Skoda RC. A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. Haematologica 2008, 93(5); 706–14.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18367486
2008 Mayerhofer M, Gleixner KV, Hoelbl A, Florian S, Hoermann G, Aichberger KJ, Bilban M, Esterbauer H, Krauth MT, Sperr WR, Longley JB, Kralovics R, Moriggl R, Zappulla J, Liblau RS, Schwarzinger I, Sexl V, Sillaber C, Valent P. Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens. The Journal of Immunology, 2008, 180: 5466–5476.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18390729
2008 Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, Ferrari M, Gisslinger H, Kralovics R, Cremonesi L, Skoda R, Cazzola M. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008, 111:1686–1689.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/17984312
2009 Buxhofer-Ausch V, Gisslinger H, Berg T, Gisslinger B, Kralovics R. Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofifibrosis. Eur J Haematol, 2009 Feb;82(2):161-3.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19018861
2009 Olcaydu D, Harutyunyan A, Jäger R, Berg T, Gisslinger B, Pabinger I, Gisslinger H, Kralovics R. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nature Genetics, 2009 41(4):450-4. Epub 2009 Mar 15.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19287385
2009 Olcaydu D, Skoda RC, Looser R, Li S, Cazzola M, Pietra D, Passamonti F, Lippert E, Carillo S, Girodon F, Vannucchi A, Reading NS, Prchal JT Ay C, Pabinger I, Gisslinger H, Kralovics R. The GGCC haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation positive polycythemia vera. Leukemia, 2009 Oct;23(10):1924-6. Epub 2009 May 14.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19440215
2009 Schaub FX, Jäger R, Looser R, Hao-Shen H, Hermouet S, Girodon F, Tichelli A, Gisslinger H, Kralovics R, Skoda RC. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood, 2009 Feb;113(9):2022-7.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19047681
2010 Jager R, Gisslinger H, Passamonti F, Rumi E, Berg T, Gisslinger B, Pietra D, Harutyunyan A, Klampfl T, Olcaydu D, Cazzola M, Kralovics R. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia. 2010 Jul;24(7):1290-8. Epub 2010 May 27.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20508609
2010 Jager R, Kralovics R. Molecular basis and clonal evolution of myeloproliferative neoplasms. Haematologica. 2010 Apr;95(4):526-9.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/20378573
2010 Jager R, Kralovics R. Molecular pathogenesis of Philadelphia chromosome-negative chronic myeloproliferative neoplasms. Curr Cancer Drug Targets. 2010 Nov 10.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21062246
2011 Carillo S, Henry L, Lippert E, Girodon F, Guiraud I, Richard C, Dubois Galopin F, Cleyrat C, Jourdan E, Kralovics R, Hermouet S, Lavabre-Bertrand T. Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations – clinical relevance in the monitoring of polycythemia. J Mol Diagn. 2011 May;13(3):263-70.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21497288
2011 Harutyunyan A, Gisslinger B, Klampfl T, Berg T, Bagienski K, Gisslinger H, Kralovics R. Rare germline variants in regions of loss of heterozygosity may influence clinical course of hematological malignancies. Leukemia. 2011 Nov;25(11):1782-4.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21681190
2011 Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic transformation. N Engl J Med. 2011 Feb 3;364(5):488-90.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21288114
2011 Huang R, Jaritz M, Guenzl P, Vlatkovic I, Sommer A, Tamir IM, Marks H, Klampfl T, Kralovics R, Stunnenberg HG, Barlow DP, Pauler FM. An RNA-Seq strategy to detect the complete coding and non-coding transcriptome including full-length imprinted macro ncRNAs. PLoS One. 2011;6(11):e27288.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22102886
2011 Jager R, Kralovics R. Molecular pathogenesis of Philadelphia chromosome negative chronic myeloproliferative neoplasms. Curr Cancer Drug Targets. 2011 Jan;11(1):20-30.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21062246
2011 Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K, Olcaydu D, Passamonti F, Rumi E, Pietra D, Jager R, Pieri L, Guglielmelli P, Iacobucci I, Martinelli G, Cazzola M, Vannucchi AM, Gisslinger H, Kralovics R. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood. 2011 Jul 7;118(1):167-76.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21531982
2011 Olcaydu D, Rumi E, Harutyunyan A, Passamonti F, Pietra D, Pascutto C, Berg T, Jager R, Hammond E, Cazzola M, Kralovics R. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica. 2011 Mar;96(3):367-74.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21173100
2011 Rumi E, Harutyunyan A, Elena C, Pietra D, Klampfl T, Bagienski K, Berg T, Casetti I, Pascutto C, Passamonti F, Kralovics R, Cazzola M. Identification of genomic aberrations associated with disease transformation by means of highresolution SNP array analysis in patients with myeloproliferative neoplasm. Am J Hematol. 2011 Dec;86(12): 974-9.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21953568
2011 Vilaine M, Olcaydu D, Harutyunyan A, Bergeman J, Tiab M, Ramee JF, Chen JM, Kralovics R, Hermouet S. Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm. Blood. 2011 Dec 8;118(24):6468-70.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22161852
2011 Zimprich A, Benet-Pages A, Struhal W, Graf E, Eck SH, Offman MN, Haubenberger D, Spielberger S, Schulte EC, Lichtner P, Rossle SC, Klopp N, Wolf E, Seppi K, Pirker W, Presslauer S, Mollenhauer B, Katzenschlager R, Foki T, Hotzy C, Reinthaler E, Harutyunyan A, Kralovics R, Peters A, Zimprich F, Brucke T, Poewe W, Auff E, Trenkwalder C, Rost B, Ransmayr G, Winkelmann J, Meitinger T, Strom TM. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet. 2011 Jul 15;89(1):168-75.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21763483
2012 Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, Cazzola M, Vannucchi AM, Hoffman R, Barbui T, Thiele J, Van Etten RA, Mughal T, Tefferi A. Unraveling the genetic underpinnings of myeloproliferative neoplasm and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol. 2012 May;87(5):562-8. doi: 10.1002/ajh.23169. Epub 2012 Mar 28.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22460584
2012 Bento C, Maia TM, Milosevic JD, Carreira IM, Kralovics R, Ribeiro ML. Beta thalassemia major due to acquired uniparental disomy in a previously healthy adolescent. Haematologica. 2012 Aug 8. [Epub ahead of print].
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22875618
2012 Clarke M, Dumon S, Ward C, Jäger R, Freeman S, Dawood B, Sheriff L, Lorvellec M, Kralovics R, Frampton J, García P. MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia. Leukemia. 2012 Aug 22. doi: 10.1038/leu.2012.241.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22910183
2012 Harutyunyan AS, Kralovics R. Role of germline genetic factors in MPN pathogenesis. Hematol Oncol Clin North Am. 2012 Oct;26(5):1037-51.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23009936
2012 Milosevic JD, Kralovics R. Genetic and epigenetic alterations of myeloproliferative disorders. Int J Hematol. 2012 Dec 12. [Epub ahead of print].
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23233154
2012 Milosevic JD, Puda A, Malcovati L, Berg T, Hofbauer M, Stukalov A, Klampfl T, Harutyunyan AS, Gisslinger H, Gisslinger B, Burjanivova T, Rumi E, Pietra D, Elena C, Vannucchi AM, Doubek M, Dvorakova D, Robesova B, Wieser R, Koller E, Suvajdzic N, Tomin D, Tosic N, Colinge J, Racil Z, Steurer M, Pavlovic S, Cazzola M, Kralovics R. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Am J Hematol. 2012 Nov;87(11):1010-6.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22887079
2012 Puda A, Milosevic JD, Berg T, Klampfl T, Harutyunyan AS, Gisslinger B, Rumi E, Pietra D, Malcovati L, Elena C, Doubek M, Steurer M, Tosic N, Pavlovic S, Guglielmelli P, Pieri L, Vannucchi AM, Gisslinger H, Cazzola M, Kralovics R. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol. 2012 Mar;87(3):245-50. doi: 10.1002/ajh.22257. Epub 2011 Dec 21.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22190018
2013 Cleary C, Kralovics R. Molecular basis and clonal evolution of myeloproliferative neoplasms. Clin Chem Lab Med. 2013 Oct 1; 51(10):1889-96.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23729579
2013 Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka H-M, Kralovics R, Petrides PE, Gastl G, Gisslinger B, Muellauer L, Schlögl E, Indrak K, Pytlik R, Briere K, Kiladjian JJ, Beykirch M, Gaede B, Griesshammer M, Herbrik-Zipp M, Hurtz HJ, Jacobs G, Jäcki SH, Keilholz U, MezgerJ, Schlag P, Schriever F, Masszi T, Sacchi S, Griniptì R ,Tavoriene I, Dmoszynska A, Hellman A, Jedrzejczak WW, Robak T, SkotnickiA, Goh YT, Cernelc P. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 March 7; 121(10): 1720–1728.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23315161
2013 Rommer A, Steinleitner K, Hackl H, Schneckenleithner C, Engelmann M, Scheideler M, Vlatkovic I, Kralovics R, Cerny-Reiterer, Valent P, Sill H, Wieser R. Overexpression of primary microRNA 221/222 in acute myeloid leukemia. BMC Cancer. 2013; 13: 364.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23895238
2013 Rumi E, Milosevic JD, Casetti I, Dambruoso I, Pietra D, Boveri E, Boni M, Bernasconi P, Passamonti F, Kralovics R, Cazzola M. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol. 2013 Jun 10; 31(17):e269-71.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23630205
2013 Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24325356
2013 Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2013 Dec 23. [Epub ahead of print]
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24366362
2013 Gisslinger H, Schalling M, Gisslinger B, Skrabs C, Müllauer L, Kralovics R. Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis. Am J Hematol. 2013 Nov 25. doi: 10.1002/ajh.23637. [Epub ahead of print]
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24273107
2013 Them NC, Kralovics R. Genetic Basis of MPN: Beyond JAK2-V617F. Curr Hematol Malig Rep. 2013 Dec;8(4):299-306. doi: 10.1007/s11899-013-0184-z.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24190690
2014 Rumi E, Harutyunyan AS, Pietra D, Milosevic JD, Casetti IC, Bellini M, Them NC, Cavalloni C, Ferretti VV, Milanesi C, Berg T, Sant'antonio E, Boveri E, Pascutto C, Astori C, Kralovics R, Cazzola M. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood. 2014 Apr 10;123(15):2416-9. doi: 10.1182/blood-2014-01-550434. Epub 2014 Feb 19.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24553179
2014 Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda RC. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014 Apr 3;123(14):2220-8. doi: 10.1182/blood-2013-11-537167. Epub 2014 Jan 29.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24478400
2014 Buxhofer-Ausch V, Olcaydu D, Gisslinger B, Schalling M, Frantal S, Thiele J, Müllauer L, Kvasnicka HM, Watzke H, Kralovics R, Gisslinger H. Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia. Eur J Haematol. 2014 Aug;93(2):103-11. doi: 10.1111/ejh.12307. Epub 2014 Apr 23.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24617727
2014 Marty C, Saint-Martin C, Pecquet C, Grosjean S, Saliba J, Mouton C, Leroy E, Harutyunyan AS, Abgrall JF, Favier R, Toussaint A, Solary E, Kralovics R, Constantinescu SN, Najman A, Vainchenker W, Plo I, Bellanné-Chantelot C. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood. 2014 Feb 27;123(9):1372-83. doi: 10.1182/blood-2013-05-504555. Epub 2014 Jan 7.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24398328
2014 Cazzola M, Kralovics R. JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med. 2014 Mar 20;370(12):1169. doi: 10.1056/NEJMc1400499. Comment.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24645955
2014 Broséus J, Lippert E, Harutyunyan AS, Jeromin S, Zipperer E, Florensa L, Milosevic JD, Haferlach T, Germing U, Luño E, Schnittger S, Kralovics R, Girodon F. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2014 Jun;28(6):1374-6. doi: 10.1038/leu.2014.49. Epub 2014 Jan 30.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24476766
2014 Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014 Jun 12;123(24):3714-9. doi: 10.1182/blood-2014-03-530865. Epub 2014 Apr 30.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24786775
2014 Jäger R, Harutyunyan AS, Rumi E, Pietra D, Berg T, Olcaydu D, Houlston RS, Cazzola M, Kralovics R. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. Am J Hematol. 2014 Sep 5. doi: 10.1002/ajh.23842.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25196853
2015 Harutyunyan AS, Jäger R, Chen D, Berg T, Rumi E, Gisslinger B, Pietra D, Gisslinger H, Cazzola M, Kralovics R. Allelic imbalance in CALR somatic mutagenesis. Leukemia. 2015 Jan 8. doi: 10.1038/leu.2015.3
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25567134
2015 Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, Aranaz P, White HE, Waghorn K, Lin F, Chase A, Baxter EJ, Maclean C, Nangalia J, Chen E, Evans P, Short M, Jack A, Wallis L, Oscier D, Duncombe AS, Schuh A, Mead AJ, Griffiths M, Ewing J, Gale RE, Schnittger S, Haferlach T, Stegelmann F, Döhner K, Grallert H, Strauch K, Tanaka T, Bandinelli S, Giannopoulos A, Pieri L, Mannarelli C, Gisslinger H, Barosi G, Cazzola M, Reiter A, Harrison C, Campbell P, Green AR, Vannucchi A, Cross NC. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun. 2015 Apr 7;6:6691. doi: 10.1038/ncomms7691.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25849990
2015 Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Zagrijtschuk O, Klade C, Greil R, Gisslinger H, Kralovics R. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015 Apr;90(4):288-94. doi: 10.1002/ajh.23928. Epub 2015 Mar 2.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25545244
2015 Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu RI, Marty C, Gryshkova V, Defour JP, Vertenoeil G, Ngo A, Koay A, Raslova H, Courtoy PJ, Choong ML, Plo I, Vainchenker W, Kralovics R, Constantinescu SN. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood. 2015 Dec 14. pii: blood-2015-11-681932.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26668133
2015 Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26261238
2015 Harutyunyan AS, Giambruno R, Krendl C, Stukalov A, Klampfl T, Berg T, Chen D, Milosevic Feenstra JD, Jäger R, Gisslinger B, Gisslinger H, Rumi E, Passamonti F, Pietra D, Müller AC, Parapatics K, Breitwieser FP, Herrmann R, Colinge J, Bennett KL, Superti-Furga G, Cazzola M, Hammond E, Kralovics R. Germline RBBP6 mutations in familial myeloproliferative neoplasms. Blood. 2015 Nov 16. pii: blood-2015-09-668673.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26574608
2015 Licciardello MP, Müllner MK, Dürnberger G, Kerzendorfer C, Boidol B, Trefzer C, Sdelci S, Berg T, Penz T, Schuster M, Bock C, Kralovics R, Superti-Furga G, Colinge J, Nijman SM, Kubicek S. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation. Oncogene. 2015 Jul;34(29):3780-90. doi: 10.1038/onc.2014.319. Epub 2014 Sep 29.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25263445
2015 Marty C, Pecquet C, Nivarthi H, Elkhoury M, Chachoua I, Tulliez M, Villeval JL, Raslova H, Kralovics R, Constantinescu SN, Plo I, Vainchenker W. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2015 Nov 25. pii: blood-2015-11-679571.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26608331
2015 Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, Kubesova B, Pietra D, Gisslinger B, Milanesi C, Jäger R, Chen D, Berg T, Schalling M, Schuster M, Bock C, Constantinescu SN, Cazzola M, Kralovics R. Whole exome sequencing identifies novel MPL and JAK2 mutations in triple negative myeloproliferative neoplasms. Blood. 2015 Sep 30. pii: blood-2015-07-661835.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26423830
2015 Rumi E, Milosevic JD, Selleslag D, Casetti I, Lierman E, Pietra D, Cavalloni C, Bellini M, Milanesi C, Dambruoso I, Astori C, Kralovics R, Vandenberghe P, Cazzola M. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Ann Hematol. 2015 Nov;94(11):1927-8. doi: 10.1007/s00277-015-2451-7. Epub 2015 Jul 23.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26202607
2016 Buxhofer-Ausch V, Gisslinger B, Schalling M, Gleiss A, Schiefer AI, Müllauer L, Thiele J, Kralovics R, Gisslinger H. Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis. Br J Haematol. 2016 Jul 19. doi: 10.1111/bjh.14202.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/27432009
2016 Kapralova K, Horvathova M, Pecquet C, Fialova Kucerova J, Pospisilova D, Leroy E, Kralova B, Milosevic Feenstra JD, Schischlik F, Kralovics R, Constantinescu SN, Divoky V. Cooperation of germline JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia. Blood. 2016 Jul 7. pii: blood-2016-02-698951.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/27389715
2016 Kornienko AE, Dotter CP, Guenzl PM, Gisslinger H, Gisslinger B, Cleary C, Kralovics R, Pauler FM, Barlow DP. Long non-coding RNAs display higher natural expression variation than protein-coding genes in healthy humans. Genome Biol. 2016 Jan 29;17(1):14. doi: 10.1186/s13059-016-0873-8.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26821746
2016 Nivarthi H, Chen D, Cleary C, Kubesova B, Jäger R, Bogner E, Marty C, Pecquet C, Vainchenker W, Constantinescu SN, Kralovics R. Thrombopoietin receptor is required for the oncogenic function of CALR mutants. Leukemia. 2016 Feb 17. doi: 10.1038/leu.2016.32.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26883579
2016 Nivarthi H, Gordziel C, Themanns M, Kramer N, Eberl M, Rabe B, Schlederer M, Rose-John S, Knösel T, Kenner L, Freund P, Aberger F, Han X, Kralovics R, Dolznig H, Jennek S, Friedrich K, Moriggl R. The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth. Oncotarget. 2016 May 12. doi: 10.18632/oncotarget.9315.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/27191495
2016 Rumi E, Harutyunyan AS, Pietra D, Feenstra JD, Cavalloni C, Roncoroni E, Casetti I, Bellini M, Milanesi C, Renna MC, Gotti M, Astori C, Kralovics R, Cazzola M. LNK mutations in familial myeloproliferative neoplasms. Blood. 2016 Jul 7;128(1):144-5. doi: 10.1182/blood-2016-04-711150
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/27216218
2016 Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, Geier F, Dirnhofer S, Guglielmelli P, Vannucchi AM, Feenstra JD, Kralovics R, Orkin SH, Skoda RC. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med. 2016 Jul 25;213(8):1479-96. doi: 10.1084/jem.20151136.
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/27401344
2016 Antic DA, Vukovic VM, Milosevic Feenstra JD, Kralovics R, Bogdanovic AD, Dencic Fekete MS, Mihaljevic BS. 8p11 myeloproliferative syndrome: diagnostic challenges and pitfalls. J BUON. 2016 May-Jun;21(3):745-9.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/27569099
2016 Javaheri T, Kazemi Z, Pencik J, Pham HT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DN, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R. Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation. Cell Death Dis. 2016 Oct 13;7(10):e2419. doi: 10.1038/cddis.2016.268.
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133963/
2016 Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2016 Dec 27. pii: blood-2016-10-695940. doi: 10.1182/blood-2016-10-695940.
Abstract: http://www.bloodjournal.org/content/early/2016/12/27/blood-2016-10-695940